SpringWorks Therapeutics News

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue n

Simply Wall StMay 11 07:57

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ

GlobeNewswireMay 8 06:00

HC Wainwright & Co. : The SpringWorks Therapeutics (SWTX.US) rating was confirmed and adjusted from buy to buy, with a target price of $74.00.

HC Wainwright & Co. : The SpringWorks Therapeutics (SWTX.US) rating was confirmed and adjusted from buy to buy, with a target price of $74.00.

Zhitong FinanceMay 6 05:40

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics with a Buy and maintains $74 price target.

Analyst UpgradesMay 6 05:35

SpringWorks Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 64.04% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/06/2024 66.26% JP Morgan $74 → $75 Mai

BenzingaMay 6 05:34

Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)

TipRanksMay 6 02:01

Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference

The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:Financial Performance:SpringWorks Therapeutics reported revenue of $21 million after the succes

Futu NewsMay 5 01:40 · Conference Call

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Yahoo FinanceMay 3 07:41

Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating

SpringWorks Therapeutics (SWTX) has an average rating of buy and price targets ranging from $58 to $80, according to analysts polled by Capital IQ. Price: 43.54, Change: -3.30, Percent Change: -7.05

MT NewswiresMay 2 11:25

SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.

SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.

BenzingaMay 2 09:52

Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline

TipRanksMay 2 08:37

SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX

SpringWorks Therapeutics Cash, Cash Equivalents and Marketable Securities Were $573M as of March 31 >SWTX

Dow JonesMay 2 05:33

SpringWorks Therapeutics Q1 2024 GAAP EPS $(1.18) Misses $(1.16) Estimate, Sales $21.006M Beat $12.206M Estimate

SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.16) by 1.72 percent. This is unchanged from the same period las

BenzingaMay 2 05:32

Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, Vs. Street Est of $13.1M

06:31 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M

MT NewswiresMay 2 05:31

SpringWorks Therapeutics 1Q Loss $87.4M >SWTX

SpringWorks Therapeutics 1Q Loss $87.4M >SWTX

Dow JonesMay 2 05:30

SpringWorks Therapeutics 1Q Loss/Shr $1.18 >SWTX

SpringWorks Therapeutics 1Q Loss/Shr $1.18 >SWTX

Dow JonesMay 2 05:30

Springworks Therapeutics (SWTX) Receives a Buy From Barclays

TipRanksMay 2 02:50

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will

GlobeNewswireApr 18 06:00

Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year

Seeking AlphaMar 10 12:08

Correction to SpringWorks Therapeutics Rating on March 6

JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00/share. "SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan" at 6:49 a.m. ET on March 6 i

Dow JonesMar 8 10:04